Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.

Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie (ABBV) shares continue to pop in Friday trading after raising its revenue ...

For those who may need relief from pain, Journavx symbolizes not only a new option but also a significant step forward in how we can tackle the challenges of pain management in the 21st century. The ...

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex ...

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.

Vertex Pharmaceuticals Up Nearly 6%, on Pace for Largest Percent Increase Since December 2023 — Data Talk Vertex Pharmaceuticals Incorporated (VRTX) is currently at $464.17, up $25.77 or 5.88% --Would ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel declines after ...